R-2-hydroxyglutarate (R-2HG), an oncometabolite resulting from the conversion of α-ketoglutarate by mutant IDH1/2 enzymes, has also been shown to specifically inhibit FTO and proliferation of leukemic or GBM cells [13]. Here, FTO is linked to glioblastoma.